NeoGenomics Inc (NEO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
NeoGenomics Inc stock (NEO) is currently trading at $7.77. NeoGenomics Inc PS ratio (Price-to-Sales) is 1.42. Analyst consensus price target for NEO is $14.81. WallStSmart rates NEO as Underperform.
- NEO PE ratio analysis and historical PE chart
- NEO PS ratio (Price-to-Sales) history and trend
- NEO intrinsic value — DCF, Graham Number, EPV models
- NEO stock price prediction 2025 2026 2027 2028 2029 2030
- NEO fair value vs current price
- NEO insider transactions and insider buying
- Is NEO undervalued or overvalued?
- NeoGenomics Inc financial analysis — revenue, earnings, cash flow
- NEO Piotroski F-Score and Altman Z-Score
- NEO analyst price target and Smart Rating
NeoGenomics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
NeoGenomics Inc (NEO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, eps growth. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
NeoGenomics Inc (NEO) Key Strengths (4)
Earnings per share surging 130.60% year-over-year
102.75% of shares held by major funds and institutions
Paying $1.42 for every $1 of annual revenue
Trading at 1.24x book value, attractively priced
Supporting Valuation Data
NeoGenomics Inc (NEO) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Paying a premium for growth, expensive relative to earnings expansion
Small-cap company with higher risk but more growth potential
Solid revenue growth at 10.60% per year
Supporting Valuation Data
NeoGenomics Inc (NEO) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Price/Sales. Valuation metrics including Price/Sales (1.42), Price/Book (1.24) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 130.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including PEG Ratio (2.09) suggest expensive pricing. Growth concerns include Revenue Growth at 10.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -12.40%, Operating Margin at -6.56%, Profit Margin at -14.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -12.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 10.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (EPS Growth, Institutional Own.) and negatives (Return on Equity, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NEO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NEO's Price-to-Sales ratio of 1.42x trades at a deep discount to its historical average of 11.71x (0th percentile). The current valuation is 99% below its historical high of 120.52x set in Nov 2006, and 1% above its historical low of 1.41x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for NeoGenomics Inc (NEO) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
NeoGenomics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 727M with 11% growth year-over-year. The company is currently unprofitable, posting a -14.8% profit margin.
Key Findings
The company is unprofitable with a -14.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.64, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact NeoGenomics Inc.
Bottom Line
NeoGenomics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About NeoGenomics Inc(NEO)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.